News Archive

15.04.2024 Presse

Indivumed Omics Hub and Clinical Network Collaborations Powering Precision Medicine Research Publications

Indivumed GmbH announced the fourth research publication enabled by the Indivumed Omics Hub. An interface for members of the Indivumed Global Clinical Network, the Omics Hub provides clinicians with direct access to curated multi-omics data derived from their patients. With access to both individual and cohort data, the Omics Hub enables quick and efficient precision oncology research.

11.12.2023 Presse

Indivumed Hosts Onco AI-Med Annual Board Meeting in Hamburg

Onco AI-Med is an international collaborative alliance founded by Indivumed to advance personalized medicine in cancer by bringing together the combined knowledge and experience of oncologists from leading cancer clinics and research institutions around the world. Indivumed Therapeutics welcomed members of the Oncology Alliance For Individualized Medicine to its global headquarters in Hamburg, Germany for the Onco AI-Med annual board meeting.

07.12.2023 Presse

BIO Deutschland Yearbook 2023/2024

We are pleased to again be featured in the BIO Deutschland Yearbook for 2023/2024 and proud to be a part of the rapidly growing European biotech industry, looking forward to continuing our success in 2024. Read our feature interview and profile here.

28.11.2023 Presse

Standardizing tissue quality: Your key to accurate early discovery insights

In precision oncology, tissue quality plays a pivotal role in maintaining data integrity. We explore the impact of standardizing tissue collection and processing on data quality, and how this helps enhance patient outcomes as well as our understanding of cancer.

21.09.2023 Presse

Precision therapeutics: optimizing early discovery

Precision medicine tailors therapeutics to individual patients’ diseases, and is seen as the future of clinical practice. With significant time and financial investments being made in developing therapeutics, the ultimate success of patient-data driven precision therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.

28.07.2023 Presse

Where the medicine of the future is already being lived in the present

More than 20 years ago, Indivumed set out to create a solid database for the individualized cancer therapy of the future. Today, founder and CEO Prof. Dr. Hartmut Juhl considers himself to have made considerable progress along this path, not least thanks to his company's unique database. In an interview with Wirtschaftsforum, the passionate entrepreneur talked about the future prospects.

24.07.2023 Presse

Applied Molecular-Based Quality Control of Biobanked Samples for Multi-Omics Approach

Read our at MDPI newly published paper on "Applied Molecular-Based Quality Control of Biobanked Samples for Multi-Omics Approach".

06.06.2023 Presse

Optimizing early discovery within precision therapeutics

Precision medicine involves tailoring a therapeutic to a patients’ disease. Here, we delve into the critical role played by the quality of the samples, the data, and the analysis in the development of these targeted therapies. Read the full article.

04.04.2023 Presse

Indivumed Evolves into Indivumed Therapeutics to Focus on Data and AI-Driven Advancement of Precision Oncology

Sale of Indivumed’s Service Business to Crown Bioscience Enables Creation of Oncology R&D Powerhouse

25.01.2023 Presse

Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank

Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH. A Sales and Purchase Agreement (SPA) between both parties was executed on December 29, 2022, and subject to customary closing adjustments the transaction is expected to close in April 2023.

23.12.2022 Presse

Ending the year - Today. Tomorrow. Together.

A review on 2022 and Indivumed's 20 year long history, and outlook, and thank you

07.09.2022 Presse

Indivumed and CELLphenomics Announce Partnership

Indivumed GmbH and CELLphenomics GmbH today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to identify therapeutically relevant targets and validate these targets in-vitro. The partnership will accelerate cancer drug development by linking in-silico target discovery and development with matched patient-derived tumor models for downstream validation.

28.04.2022 Presse

Indivumed Expands Its Certified Provider Portfolio

Today, we are happy to announce that Indivumed is now a “Certified Service Provider” of the Spatial Transcriptomics technology (Visium Spatial Gene Expression) by 10x Genomics not only for fresh frozen- but for FFPE tissue as well.

05.04.2022 Presse

Indivumed Celebrates 20th Anniversary

Indivumed GmbH today celebrated the company’s 20th anniversary milestone. Founded in Hamburg, Germany on April 5, 2002, Indivumed has rapidly expanded to become a leading innovator in the field of precision oncology.

17.01.2022 Presse

Indivumed receives EU funding from ERDF structural fund

Indivumed receives EU funding from ERDF structural fund

12.12.2021 Presse

Indivumed appoints Dr. Stephan Schüller as CFO

Indivumed is pleased to announce that Dr. Stephan Schüller has joined Indivumed as Chief Financial Officer. With more than 30 years of experience as a business executive, professor, and board member, Dr. Schüller brings highly valuable knowledge and perspectives to Indivumed.

16.11.2021 Presse

Northwell and Indivumed reach biobank milestone

More than 1,000 consented Northwell Health patients have donated their biospecimens to continue further cancer research

26.10.2021 Presse

Indivumed and Biognosys Extend Strategic Partnership

The Partnership Will Combine Each Company’s Capabilities in Omics Research to Provide Biopharma Customers with Immunopeptidomics Insights for Drug Discovery

10.08.2021 Presse

VERAXA Biotech and Indivumed Cooperate on the Development of Precision Oncology Antibody Drugs

VERAXA Biotech GmbH and Indivumed GmbH announced today their agreement to jointly discover modulatory and functional antibodies against several targets that are relevant for colorectal cancer. The targets have been identified by Indivumed’s discovery solution platform nRavel®, only two months after its launch. The antibody development and commercialization will be performed by Indivumed’s subsidiary, Ix Therapeutics.

09.06.2021 Presse

Indivumed becomes Certified Service Provider of the Spatial Transcriptomics technology by 10x Genomics

Indivumed became a “Certified Service Provider” of the Spatial Transcriptomics technology (Visium Spatial Gene Expression) by 10x Genomics. In combination with the high quality multi-omics tissue Indivumed offers the whole workflow for customer research projects.

02.06.2021 Presse

Indivumed Launches nRavel™ AI Platform

Indivumed GmbH today announced the launch of nRavel™, a unique AI discovery platform for oncology and precision medicine. The platform combines IndivuType’s deep multi-omics data with elaborate disease models, high-powered automated Machine Learning tools, and a comprehensive suite of advanced analytics tools. Together this creates an unparalleled engine for generating new discoveries and insights into cancer biology.

17.05.2021 Presse

Indivumed Joins KHR Biotec

Indivumed GmbH CEO Dr. Hartmut Juhl and University Medical Center Mainz Professor Krishnaraj Rajalingam today announced Indivumed will be joining the newly formed KHR Biotech GmbH – a spin-off biopharma company from University Mainz. The new company will combine Prof. Rajalingam’s research and scientific approach with Indivumed’s database and AI capabilities in order to bring new compounds targeting pertinent oncogenic signaling pathways into the clinical phase.

06.05.2021 Presse

Indivumed Expands Digital Pathology Asset and Analysis Capacity

Indivumed today announced a joint research collaboration to expand IndivuType by adding digital pathology images and data using cutting-edge technology from the Institute for Cancer Genetics and Informatics at Oslo University Hospital, a world leader in the application of Deep Learning and AI in oncology.

18.03.2021 Presse

Indivumed Announces Expansion Into Drug Development, Formation of Ix Therapeutics

Indivumed GmbH announced today the founding of Ix Therapeutics GmbH, a joint venture with Xlife Sciences AG, which marks Indivumed’s expansion into target discovery and early cancer drug development. The collaboration opens up completely new possibilities for cancer treatment.

26.01.2021 Presse

Indivumed appoints Roald Forsberg as new Chief Business Officer

Indivumed appoints Dr. Roald Forsberg as Chief Business Officer and Head of the IndivuType Business Unit. He succeeds Fernando Andreu, who led the IndivuType Business Unit during its early phase.

05.01.2021 Presse

A retrospective and outlook

It has been a very special year – with unexpected challenges and global uncertainty putting much of the world at a standstill. With this in mind, we are grateful and proud to look back and see that Indivumed did not stand still – in the face of these challenges, we kept moving forward.

18.11.2020 Presse

Indivumed and Ultivue announce collaborative partnership

Ultivue and Indivumed today announced that the two companies have entered into a collaborative partnership to further accelerate research and drug development in the area of personalized oncology.

10.11.2020 Presse

Indivumed Launches Groundbreaking AI Platform to Leverage Multi-omics Data for Discoveries in Oncology

Analytics Platform Provides Insights into Cancer Biology, Acceleration of Drug and Diagnostic Development

03.09.2020 Presse

Indivumed Announces Global Expansion of Clinical Network to Grow IndivuType Database

First Clinics in Japan and Korea, Growth of European and South American Clinical Networks

27.08.2020 Presse

Indivumed, Gnosis Expand Partnership to Enhance AI and Machine Learning Capabilities

Partnership Will Accelerate IndivuType Database Analysis, Facilitate Discovery of Additional Drug Targets

26.08.2020 Presse

Statement from Dr. Eric L. Powell, Senior Director, Oncology Research Unit, Pfizer, on the collaboration with Indivumed

„The depth of the information contained in the IndivuType database is outstanding. Together with its AI-integrated advanced analytics platform it is a game-changer for drug discovery and development programs and we are excited about the opportunity to work with Indivumed.“

14.07.2020 Presse

First joint webinar of Evotec and Indivumed demonstrates the power of Indivumed’s multi-omics database IndivuType for drug development

On July 8, Indivumed hosted a webinar together with our partner Evotec on “Target Discovery for Colon and Lung Cancer through Multi-omics Analysis of High-Quality Patient Samples.”

18.05.2020 Presse

Indivumed Global Alliance to Broaden Access to Multi-Omics Algorithms

We are proud to share our recent Precision Oncology News feature story about the launch of Onco AI-Med - a partnership between select leading cancer clinics and research institutions all over the world to advance precision oncology.

21.04.2020 Presse

Indivumed, Personalis Partner to Enhance Genomic Sequencing Capabilities

Collaboration to Advance Cancer Genomics Insights to Enable Novel Discoveries

15.04.2020 Presse

Indivumed Launches Global Oncology Alliance For Individualized Medicine ("Onco AI-Med")

Indivumed GmbH announced today the launch of the Oncology Alliance for Individualized Medicine Onco AI-Med, an international collaborative alliance to advance personalized medicine in cancer through Indivumed’s true multi-omics database, IndivuType

09.04.2020 Presse

Indivumed fights COVID-19

In these times when the world is fighting with the COVID-19 pandemics, testing is crucial.

23.03.2020 Presse

Statement COVID-19 Virus – Information to our customers

In light of the situation created by the global outbreak of COVID-19, our responsibility towards the communities in which we live and operate is the guiding principle for all of us at Indivumed.

06.02.2020 Presse

Indivumed Biobank plays a meaningful role in the ICGC/TCGA Pan-Cancer Project to Decipher the Cancer Genome

Indivumed is delighted to announce that our unique, high-quality tissue biobank played a meaningful role in the success of the Pan-Cancer Project, the largest, most comprehensive analysis of cancer genomes to date.

23.01.2020 Presse

EVOTEC AND INDIVUMED ANNOUNCE SECOND JOINT DRUG DISCOVERY PROGRAMME

Evotec SE and Indivumed GmbH today announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (“NSCLC”).

14.01.2020 Presse

Indivumed Announces Expansion of the IndivuType Global Cancer Database in Italy

Collaboration with Tor Vergata University Hospital of Rome Will Be Used to Discover New Mechanisms and Biomarkers in Cancer

02.12.2019 Presse

Indivumed Announces Strategic Partnership with Biognosys

This partnership represents the next step in enriching IndivuType multi-omics cancer database with proteome-level data from thousands of samples using Biognosys’ cutting-edge proteomics technology to enable novel discoveries in cancer biology.

23.10.2019 Presse

Indivumed is pleased to announce that we are joining the 25th Bio-Europe

BIO-Europe® takes place annually in changing cities and is an international forum for the promotion of corporate development between pharmaceutical, financial and biotechnology companies.

30.09.2019 Presse

Evotec and Indivumed achieve milestone in joint strategic drug discovery collaboration

Evotec SE and Indivumed GmbH announced today that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer.

31.05.2019 Presse

Indivumed launches first real multi-omics cancer platform to advance precision oncology

Integrated global oncology experts shift the precision medicine paradigm

20.05.2019 Presse

Indivumed and Gnosis Partner to Add Artificial Intelligence Capabilities to Indivumed´s Platform for multi-omics Cancer Research

Hamburg, Germany (May 20, 2019) Indivumed announced today its partnership with Gnosis Data Analysis, a leading provider of automated Machine Learning and data-analytics solutions.

26.04.2019 Presse

Ingress-health and Indivumed announce an international partnership on real-world evidence studies in oncology

Ingress-health B.V. and Indivumed GmbH announced today the launch of an exclusive partnership on real-world evidence (RWE) studies in oncology.

11.04.2019 Presse

Evotec and Indivumed announce strategic drug discovery collaboration on precision medicine for colorectal cancer

The collaboration leverages indivumed’s true multi-omics cancer database “indivutype” and evotec’s drug discovery platforms to identify new therapeutics for colorectal cancer

28.03.2019 Presse

Indivumed Partners with Flagship Biosciences to Provide Global Tissue-Based Diagnostics Services

Hamburg, Germany and Westminster, Colorado, USA, March 28, 2019 -- Indivumed and Flagship Biosciences, Inc. are pleased to announce a partnership to expand their broad tissue-based biomarker development capabilities, as well as their clinical services to support advanced oncology diagnostics.

08.03.2019 Presse

Indivumed to attend the AACR Annual Meeting, USA, March 31–April 3,2019

The AACR Annual Meeting highlights the best cancer science and medicine from institutions all over the world. Attendees are invited to stretch their boundaries, form collaborations, attend sessions outside their own areas of expertise, and learn how to apply exciting new concepts, tools, and techniques to their own research.

21.01.2019 Presse

Next In Personalized Medicine: Cancer-Phenotyping

Hartmut Juhl will be leading a session at the Precision Medicine World Conference (PMWC), January 23, 2019 in Silicon Valley explaining how cancer phenotyping can move precision medicine beyond Genomics.

18.12.2018 Presse

Indivumed Announces an International Partnership with IMCB to Establish an Asian-Centric Multiomics Cancer Database for Personalized Oncology

Indivumed Announces an International Partnership with IMCB to Establish an Asian-Centric Multiomics Cancer Database for Personalized Oncology

05.11.2018 Presse

Indivumed opens US-Headquarter in Frederick, MD

Friday, November 2nd 2018. With a symposium about „Personalized Medicine Depends on Tissue Quality“ and an opening ceremony in presence of Benjamin Wu, Maryland Deputy Secretary of Commerce, Jan Gardner, Frederick County Executive and members of the County Council as well as 120 international guests the new Indivumed Headquarter was officially opened.

24.10.2018 Presse

Indivumed to Exhibit at the 30th EORTC-NCI-AACR SYMPOSIUM ,Dublin, November 13–16

Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2018 Symposium brings together academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.

25.07.2018 Presse

Indivumed Launches New Biospecimen Product Lines

Indivumed is known for providing high-quality, ischemia-controlled biospecimens from within our clinical network. In addition to these Premium Grade specimens, we now offer two new lines of formalin-fixed paraffin-embedded (FFPE) tissue biospecimens – Advanced Grade and Basic Grade.

25.07.2018 Presse

Indivumed Officially Launches Premium Grade Longitudinal Cell-Free Plasma Biospecimens

Indivumed is known for providing high-quality, ischemia-controlled biospecimens from within our clinical network. To further support the fight against cancer, we now offer high-quality Premium Grade longitudinal cell-free plasma specimens from within our growing oncologist network.

03.07.2018 Presse

Indivumed signs agreement with IMCB to build the first global, multiomics cancer database

Indivumed GmbH and A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore have signed an agreement to perform proteomic and phosphoproteomic analysis of thousands of tissue samples from Indivumed’s unique biobank.

27.04.2018 Presse

Indivumed to Exhibit at the 3rd Annual Advances in Immuno-Oncology Congress, London, May 24-25

Indivumed is pleased to announce that we are joining the 3rd Annual Advances in Immuno-Oncology Congress, presented by the Oxford Global.

27.03.2018 Presse

Indivumed Receives Innovation Award at EIB Venture Debt Summit

Indivumed received the 2018 Innovation Award at the inaugural EIB Venture Debt Summit held in Luxembourg on March 22, 2018.

21.02.2018 Presse

Indivumed to Exhibit at the AACR Annual Meeting, USA, April 14–18

The AACR Annual Meeting highlights the best cancer science and medicine from institutions all over the world. Please visit us at booth 2140!

16.01.2018 Presse

The Salk Institute and Indivumed Partner to Advance Global Cancer Research

Salk and Indivumed have established a strategic partnership to advance research in precision oncology and personalized medicine by utilizing the highest quality molecular and clinical data in cancer

09.01.2018 Presse

Investment Plan for Europe: EIB grants loan of EUR 40m to Indivumed

The European Investment Bank (EIB) will provide a loan of EUR 40m to Indivumed GmbH, a physician-led, integrated global oncology company providing high-content tumour data and an optimum quality biobank to third parties such as biopharmaceutical companies and research institutes.

28.11.2017 Presse

All-RAS Oncobeam Test von der BARMER erstattet

In einer gemeinsamen Veranstaltung informierten die BARMER, IndivuTest und LADR Der Laborverbund über „Liquid Biopsy: Moderne Tumordiagnostik aus dem Blut“.

23.11.2017 Presse

The Importance of Tissue Quality for Personalized Medicine

Leading experts of the European Society of Digestive Oncology (ESDO) in the field of gastrointestinal cancer discussed new recommendations for the clinical relevance of molecular diagnostics during the 17th European Society for Medical Oncology (ESMO) world congress on gastrointestinal cancer in Barcelona.

15.11.2017 Presse

Indivumed to Exhibit at Molecular Med Tri-Con in San Francisco, USA, February 11–16

Molecular Med Tri-Con 2018 is one of the world’s leading international events in the field of drug discovery, development, and diagnostics.

15.11.2017 Presse

Dual IHC and Quantitative Image Analysis Evaluating Immune Tumor Microenvironments

It was our great pleasure to take part in the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting, held on November 8–12 in National Harbor, USA.

11.10.2017 Presse

Indivumed will exhibit at the SITC Annual Meeting in National Harbor, USA, November 8–12

The 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) is one of the premier destinations for scientific exchange, education, and networking in the cancer immunotherapy field.

19.09.2017 Presse

Indivumed and Helomics partner to unlock the power of cancer biospecimens for drug discovery and development

Indivumed GmbH (Indivumed) and Helomics® Corporation (Helomics) announce their intentions to collaborate to analyze human cancer biospecimens and annotated clinical data from consenting patients around the world, enabling cutting-edge basic and translational research in cancer.

16.08.2017 Presse

Indivumed Launches Fluorescent Multiplex IHC

Toward meeting your research needs, Indivumed is pleased to announce we have complemented our high-quality immunohistochemistry (IHC) services by offering Fluorescent Multiplex IHC with Tyramide Signal Amplification.

02.08.2017 Presse

MedStar Health Collaborates with Indivumed to Advance Precision Oncology Research

MedStar Health will collaborate with Indivumed to advance our understanding of the molecular basis of cancer through collection and analysis of biospecimens and clinical data, making possible new individualized diagnosis and treatment of cancer.

02.06.2017 Presse

Indivumed will have a booth at the T5 JobMesse (job fair) on 11 October, 2017, in Hamburg.

01.06.2017 Presse

Indivumed and Intermed to form strategic alliance

Intermed invests in Indivumed in order to accelerate the expansion of Indivumed’s worldwide leading Cancer Database.

10.05.2017 Presse

Indivumed will be participating in the ASCO annual meeting, June 2–6.

11.04.2017 Presse

Mayor Olaf Scholz honors Hamburg as international medical research location

Hamburg's First Mayor, Olaf Scholz, and international guests from science and business honored Indivumed at its 15-year anniversary.

10.04.2017 Presse

Indivumed Founder and CEO recognized for contribution to liquid biopsy innovation

Indivumed founder and CEO, Dr. Hartmut Juhl, has been recognized by the AACR for his participation in the development and commercialization of the field of liquid biopsy research.

22.02.2017 Presse

Industry leaders partner for first Indian national cancer database and biobank

Indivumed GmbH and The Indian Institute of Technology Madras (IITM), the country’s premier academic research institution, have announced a collaboration to support the first Indian national cancer database and biobank for use in precision cancer research.

31.01.2017 Presse

Indivumed to provide Regeneron with tissue samples for Oncology R&D

Indivumed GmbH has announced an agreement to provide Regeneron Pharmaceuticals, Inc. with access to Indivumed’s quality tissue sample and clinical and molecular data collection methods to support the company’s cancer research programs.

17.01.2017 Presse

Northwell Health partners with Indivumed to create cancer research biobank

Partnering with patients and physicians to collect and analyze biospecimen of cancer tissues will advance understanding of the genetics of cancer, making possible new individualized diagnostics and therapies.

10.01.2017 Presse

Indivumed joins Blood Profiling Atlas in Cancer (Blood PAC)

In collaboration with leading academic, industry and government organizations, Indivumed GmbH has joined the Blood Profiling Atlas in Cancer (Blood PAC), to advance precision diagnostics and therapeutics in cancer care for all patients.

11.08.2016 Presse

The Pacific Northwest Research Institute and Indivumed GmbH announce strategic collaboration

The Pacific Northwest Research Institute (PNRI), located in Seattle, Washington, USA and Indivumed GmbH have announced a strategic collaboration to harness the power of molecular and clinical cancer data for tailoring successful treatments for individual cancer patients.

21.07.2016 Presse

Indivumed and Definiens partner to utilize tumor tissue for drug discovery and development

Pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, Definiens, and Indivumed GmbH have announced a strategic partnership to offer a unique combination of tissue-based biomarker validation and assay development with Definiens Cognition Network Technology® for image analysis and data mining.

08.03.2016 Presse

Bialystok Medical University continues internationalization with Indivumed partnership

The Medical University of Bialystok has signed an agreement with Indivumed GmbH to establish a state-of-the-art cancer database comprised of molecular and clinical data on solid tumor tissue to be collected within the University’s hospital network.

04.02.2016 Presse

URMC Partners with Indivumed to create tissue bank for cancer research

The University of Rochester Medical Center has announced a collaboration with Indivumed GmbH to establish a bank of human tissues and tumor samples expertly preserved and stored for use in cancer research.